Navigation Links
Montreal researchers identify defects of immune cells

Researchers at Université de Montréal and the Institut de recherches cliniques de Montréal (IRCM) have successfully identified a defective immune cell population that determines susceptibility to candidiasis, a common and often debilitating infection in individuals infected with the human immunodeficiency virus (HIV). These findings, revealed using a model of candidiasis in transgenic mice expressing HIV developed by the same research group, represents a milestone in developing a treatment for the infection and, eventually, preventing it. They are described in an article of the July 1st issue of The Journal of Immunology.

Oral and esophageal Candida albicans infections, which often affect individuals infected with HIV, may limit food consumption and lead to weight loss, threatening patients' general health and well-being. Of added concern, treatment of candidiasis in these patients is often complicated by strains of Candida albicans resistant to conventional antifungal therapies. The research project was carried out jointly by Dr. Louis de Repentigny, Director of the Medical Mycology Laboratory and Professor in the Department of Microbiology and Immunology at the Faculty of Medicine of Université de Montréal, and at CHU Sainte-Justine, and Dr. Paul Jolicoeur, Director of the Molecular Biology Research Unit at the Institut de recherches cliniques de Montréal (IRCM), researcher in the Department of Microbiology and Immunology at the Faculty of Medicine of Université de Montréal, associate member of the McGill University Faculty of Medicine and holder of the Canada Research Chair on Infectious and Parasitic Diseases and Dr Zaher Hanna, Associate Director in the same Unit, researcher in the Department of Medicine at the Faculty of Medicine of Université de Montréal, associate member of the McGill University Division of Experimental Medicine.

Drs de Repentigny, Jolicœur and Hanna have for the first time succeeded in demonstrating that defective CD4+ T lymp hocytes primarily determine the susceptibility to oral candidiasis in transgenic mice expressing HIV-1 and developing an AIDS-like disease. Findings from this research further indicated that a diminution and functional defects of both dendritic cells and CD4+ cells cause susceptibility to candidiasis in these transgenic mice by preventing T lymphocyte mediated acquired immunity to Candida albicans. The results also showed extensive perturbations in the production of cytokines required for protection against oral candidiasis in the transgenic mice.

"These findings regarding the specific immune defects which trigger candidiasis are very promising," explains Dr. de Repentigny. "This new knowledge will be instrumental in designing more powerful and effective treatments, which will directly improve the health status of HIV-infected patients who suffer from candidiasis. Defective CD4+ T lymphocytes have long been suspected to be the leading cause of candidiasis, however, it never had been directly demonstrated. Now, they become designated targets for the development of novel treatments not only for candidiasis but other mucosal infections."

"Secondary infections are the major cause of morbidity and mortality in people infected by HIV/AIDS. Fungal infection due to candidiasis is one of these debilitating conditions," said Dr. Bhagirath Singh, Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Infection and Immunity. "This work provides a new understanding of why candidiasis is not controlled by the body's immune cells, particularly the CD4+ T lymphocytes. It will also help us to develop better treatments to prevent these opportunistic infections in HIV patients."


'"/>

Source:University of Montreal


Related biology news :

1. Montreal researchers probe the genetic basis of memory
2. NYU researchers simulate molecular biological clock
3. Vital step in cellular migration described by UCSD medical researchers
4. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
5. UCSD researchers maintain stem cells without contaminated animal feeder layers
6. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
7. New protein discovered by Hebrew University researchers
8. First real-time view of developing neurons reveals surprises, say Stanford researchers
9. Agilent Technologies releases automated literature search tool for biology researchers
10. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
11. Yale researchers identify molecule for detecting parasitic infection in humans
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/21/2016)... WAKEFIELD, Massachusetts , March 22, 2016 ... and facial recognition with passcodes for superior security ... MESG ), a leading provider of secure digital communications ... pilot their biometric technology and offer enterprise customers, particularly ... provide secure facial recognition and voice authentication within a ...
(Date:3/14/2016)... MELBOURNE, Florida , March 14, 2016 ... on the growing mobile commerce market, announces the airing of ... York channels starting the week of March 21 st . ... and CNBC, including its popular Squawk on the Street show. ... company focused on the growing mobile commerce market, announces the ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... LONDON , May 23, 2016 ... Boost Efficiency by 40% - Frontage Implement a Single ... Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... the United States and China ... deployed across its laboratory facilities. In addition to serving as the ...
(Date:5/20/2016)... ... , ... The leading Regenerative Veterinary Medicine Company, VetStem Biopharma ., is ... 100 of their own patients with the VetStem Cell Therapy. Each of these veterinarians ... their patients. , The veterinarians are Dr Ross Rich former owner of Cave ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located in ... office building is complete. The new structure adds a third office building to the ... USA purchased 2.4 acres of land, along with office space adjacent to the ...
(Date:5/19/2016)... 19, 2016 Regen ... PINK: RGBPP) announced today initiation of a preclinical ... blood based cancer immunotherapeutic product leveraging its NR2F6 ... described a generation of cord blood derived killer ... silencing.  The product in development will be a ...
Breaking Biology Technology: